Pub Date : 2023-03-20DOI: 10.21203/rs.3.rs-1666161/v1
F. Yıldırım, Meltem Şimşek, M. Apaydin, I. Karaman, Halil Ibrahim Dural
In this study, viral clearance (oronasopharyngeal swab RT-PCR negativity) and intensive care outcomes and risk factors affecting mortality of critically ill patients with COVID-19-related acute respiratory distress syndrome (ARDS) who received tocilizumab and favipiravir treatments together before vaccination were investigated. The data of patients who were followed up and treated between 1 July 2020 and 5 October 2020 were retrospectively analyzed. Demographic data of the patients (age, gender), oro-nasopharyngeal swab RT-PCR and classification of ARDS, respiratory support treatments, all medical treatments, and ICU outcomes were recorded. Totally, 60 patients with a median age of 69.8 [24-87], 25 females and 35 males were included in the study. Mean APACHE II score was 18.9±8.0; and SOFA score was 4.5±2.0. Thirty-four (56.7%) patients were intubated during follow-up. Tocilizumab was given on average of 2.5th day (±2.0 days). On the day of tocilizumab administration, 1 (1.7%) patient had mild ARDS, 30 (50.0%) had moderate ARDS, 29 (48.3%) had severe ARDS. PaO2/FIO2 on the day of tocilizumab administration was 96.7±36.6 mmHg. Forty (66.7%) patients died, while 20 (33.3%) patients transferred to the service. The mean length of stay in the ICU was 11.4±5.5 days. Advanced age [Hazard ratio (HR) 1.8; 95% confidense interval (CI) 0.88-0.93; p< 0.001), higher APACHE II score (HR 0.81, 95% CI 0.74-0.98; p=0.001), higher SOFA score on the day of tocilizumab administration (HR 1.47, 95% CI 0.39-0.79; p=0.001), and lower PaO2/FIO2 ratio (HR 2.54, 95% CI 2.33-3.79; p<0.001) were determined as independent risk factors for mortality. Patients who were administered tocilizumab and favipiravir together in our intensive care unit were mostly patients with severe ARDS and had higher inflammatory markers. High mortality was attributed to the use of tocilizumab as an add-on treatment, not as a routine treatment.
{"title":"Mortality Predictors of Pre-variant SARS-CoV-2 Infected ARDS Patients Receiving Favipiravir and Tocilizumab","authors":"F. Yıldırım, Meltem Şimşek, M. Apaydin, I. Karaman, Halil Ibrahim Dural","doi":"10.21203/rs.3.rs-1666161/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-1666161/v1","url":null,"abstract":"\u0000\u0000In this study, viral clearance (oronasopharyngeal swab RT-PCR negativity) and intensive care outcomes and risk factors affecting mortality of critically ill patients with COVID-19-related acute respiratory distress syndrome (ARDS) who received tocilizumab and favipiravir treatments together before vaccination were investigated.\u0000\u0000\u0000\u0000The data of patients who were followed up and treated between 1 July 2020 and 5 October 2020 were retrospectively analyzed. Demographic data of the patients (age, gender), oro-nasopharyngeal swab RT-PCR and classification of ARDS, respiratory support treatments, all medical treatments, and ICU outcomes were recorded.\u0000\u0000\u0000\u0000Totally, 60 patients with a median age of 69.8 [24-87], 25 females and 35 males were included in the study. Mean APACHE II score was 18.9±8.0; and SOFA score was 4.5±2.0. Thirty-four (56.7%) patients were intubated during follow-up. Tocilizumab was given on average of 2.5th day (±2.0 days). On the day of tocilizumab administration, 1 (1.7%) patient had mild ARDS, 30 (50.0%) had moderate ARDS, 29 (48.3%) had severe ARDS. PaO2/FIO2 on the day of tocilizumab administration was 96.7±36.6 mmHg. Forty (66.7%) patients died, while 20 (33.3%) patients transferred to the service. The mean length of stay in the ICU was 11.4±5.5 days. Advanced age [Hazard ratio (HR) 1.8; 95% confidense interval (CI) 0.88-0.93; p< 0.001), higher APACHE II score (HR 0.81, 95% CI 0.74-0.98; p=0.001), higher SOFA score on the day of tocilizumab administration (HR 1.47, 95% CI 0.39-0.79; p=0.001), and lower PaO2/FIO2 ratio (HR 2.54, 95% CI 2.33-3.79; p<0.001) were determined as independent risk factors for mortality.\u0000\u0000\u0000\u0000Patients who were administered tocilizumab and favipiravir together in our intensive care unit were mostly patients with severe ARDS and had higher inflammatory markers. High mortality was attributed to the use of tocilizumab as an add-on treatment, not as a routine treatment.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46445331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-15DOI: 10.2174/1573398x19666230315102813
Tarig Fadelelmoula, Husamuldin Hussein, M. Abdalla
Foreign body (FB) aspiration is uncommon, but potentially serious and life-threatening. Foreign body aspiration represents about 0.5% of adult bronchoscopy procedures. When bronchoscopic removal fails, the procedure should stop and a thoracic surgeon must join the procedure, and the most common surgical strategy is lobectomy. The aim of this study is to describe the outcome and safety of surgical removal of aspirated foreign bodies through minimal thoracic surgery after failure of bronchoscopic removal. This is a descriptive hospital study that involved 21 patients hospitalized in two main hospitals in Khartoum, Sudan, between September 2013 and October 2019, for the surgical removal of aspirated foreign bodies. We collected data on the demographics and clinical characteristics of the patients, the nature and anatomical location of the foreign body, and the surgical results. The descriptive hospital-based study involved 21 patients hospitalized in the thoracic surgery department in two main hospitals in Khartoum, Sudan, in the period between September 2013 and October 2019, for surgical removal of aspirated FBs following unsuccessful removal by a bronchoscope. We collected the data about patients’ demographics and clinical features, FB nature and anatomical location, and surgery outcomes. The mean age of the patients was 14 years and 12 of them were women. The incident was accidental in all patients, and the mean time between the foreign body aspiration and surgery was approximately 2 weeks. Foreign bodies were found in the right lung in 15 of the patients. All foreign body removals were achieved by minimally invasive thoracic surgery. In 17 patients, the surgery was conservative, but two patients underwent lobectomy and pneumonectomy was performed in 2 patients. The postoperative course was favorable in all patients and no deaths were reported. During the study period, 21 patients were referred for surgical removal of an aspirated FB. The mean age of participants was 14 years; 12 were females; inhalation was accidental in all cases; the average interval between the FB inhalation and surgery was 14 days. In 15 patients, the FBs were in the right tracheobronchial tree. All FB removals were by minimal thoracic surgery; 17 patients had conservative surgery, two patients had complete lung removal, and two patients had a lung lobe removed. The postoperative course was favorable in all patients, and there were no reported deaths. Minimally invasive thoracic surgery in our setting has provided a safe approach to the removal of aspirated foreign bodies after failure of bronchoscopic removal. Keywords: Bronchoscopy, foreign body, aspiration, lobectomy, pneumonectomy, scarf pin, and thoracotomy
{"title":"Safety of surgical removal of aspirated foreign bodies after failure of bronchoscopy removal","authors":"Tarig Fadelelmoula, Husamuldin Hussein, M. Abdalla","doi":"10.2174/1573398x19666230315102813","DOIUrl":"https://doi.org/10.2174/1573398x19666230315102813","url":null,"abstract":"\u0000\u0000Foreign body (FB) aspiration is uncommon, but potentially serious and life-threatening. Foreign body aspiration represents about 0.5% of adult bronchoscopy procedures. When bronchoscopic removal fails, the procedure should stop and a thoracic surgeon must join the procedure, and the most common surgical strategy is lobectomy.\u0000\u0000\u0000\u0000The aim of this study is to describe the outcome and safety of surgical removal of aspirated foreign bodies through minimal thoracic surgery after failure of bronchoscopic removal.\u0000\u0000\u0000\u0000This is a descriptive hospital study that involved 21 patients hospitalized in two main hospitals in Khartoum, Sudan, between September 2013 and October 2019, for the surgical removal of aspirated foreign bodies. We collected data on the demographics and clinical characteristics of the patients, the nature and anatomical location of the foreign body, and the surgical results.\u0000\u0000\u0000\u0000The descriptive hospital-based study involved 21 patients hospitalized in the thoracic surgery department in two main hospitals in Khartoum, Sudan, in the period between September 2013 and October 2019, for surgical removal of aspirated FBs following unsuccessful removal by a bronchoscope. We collected the data about patients’ demographics and clinical features, FB nature and anatomical location, and surgery outcomes.\u0000\u0000\u0000\u0000The mean age of the patients was 14 years and 12 of them were women. The incident was accidental in all patients, and the mean time between the foreign body aspiration and surgery was approximately 2 weeks. Foreign bodies were found in the right lung in 15 of the patients. All foreign body removals were achieved by minimally invasive thoracic surgery. In 17 patients, the surgery was conservative, but two patients underwent lobectomy and pneumonectomy was performed in 2 patients. The postoperative course was favorable in all patients and no deaths were reported.\u0000\u0000\u0000\u0000During the study period, 21 patients were referred for surgical removal of an aspirated FB. The mean age of participants was 14 years; 12 were females; inhalation was accidental in all cases; the average interval between the FB inhalation and surgery was 14 days. In 15 patients, the FBs were in the right tracheobronchial tree. All FB removals were by minimal thoracic surgery; 17 patients had conservative surgery, two patients had complete lung removal, and two patients had a lung lobe removed. The postoperative course was favorable in all patients, and there were no reported deaths.\u0000\u0000\u0000\u0000Minimally invasive thoracic surgery in our setting has provided a safe approach to the removal of aspirated foreign bodies after failure of bronchoscopic removal.\u0000\u0000\u0000\u0000Keywords: Bronchoscopy, foreign body, aspiration, lobectomy, pneumonectomy, scarf pin, and thoracotomy\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43265873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-15DOI: 10.2174/1573398x19666230315114948
R. Yazdani, M. S. Fekri, S. M. H. Bajgani, Mohsen Shafiepour, Behnam Dalfardi
Bronchial asthma is a chronic disorder with high prevalence among women. Visfatin as a pro-inflammatory adipokine has been linked to inflammatory lung diseases such as asthma and can be used as a forthcoming biomarker target to diagnose and treat asthmatic patients. Bronchial asthma is a chronic disorder with high prevalence among women. Visfatin as a pro-inflammatory adipokine has been linked to inflammatory lung diseases such as asthma and can be used as a forthcoming biomarker target to diagnose and treat asthmatic patients. The aim of this study is to evaluate plasma visfatin level and its correlation with pulmonary function of female asthmatic patients. To evaluate plasma visfatin level and its correlation with pulmonary function of female asthmatic patients. This cross-sectional study was conducted on all female asthmatic patients referred to the Be'sat Pulmonary Clinic of Kerman from 1 November 2019 to 20 February 2020. Patients with confirmed diagnosis of asthma were included. The data were collected through a checklist and the corresponding author conducted all face-to-face interviews in the physician’s office of the pulmonary clinic. Then, blood samples (5 cc) were taken from the patients to determine the plasma level of visfatin. Data was analyzed by SPSS Software. 113 women with asthma were studied. The mean ± SD age of patients was 46.71 ± 13.91 years (range: 13 to 75). The mean ± SD of visfatin plasma levels was 26.30 ± 6.98 mg/dl (range: 8.50 to 46.88). The forced expiratory volume in the first second (FEV1) had a significant and negative correlation with plasma visfatin concentrations (P-value=0.03). This cross-sectional study was conducted on all female asthmatic patients referred to the Be''sat Pulmonary Clinic of Kerman from 1 November 2019 to 20 February 2020. Patients with confirmed diagnosis of asthma were included. The data were collected through a checklist and the corresponding author conducted all face-to-face interviews in the physician’s office of the pulmonary clinic. Then, blood samples (5 cc) were taken from the patients to determine the plasma level of visfatin. Data was analyzed by SPSS Software. The results of this study indicated that plasma visfatin levels were correlated inversely with FEV1 among asthmatic women. Further studies with large samples are recommended to evaluate the role of visfatin in asthma pathogenesis. 113 women with asthma were studied. The mean ± SD age of patients was 46.71 ± 13.91 years (range: 13 to 75). The mean ± SD of visfatin plasma levels was 26.30 ± 6.98 mg/dl (range: 8.50 to 46.88). The forced expiratory volume in the first second (FEV1) had a significant and negative correlation with plasma visfatin concentrations (P-value=0.03). The results of this study indicated that plasma visfatin levels were correlated inversely with FEV1 among the asthmatic women. Further studies with large samples are recommended to evaluate the role of visfatin in asthma patho
{"title":"Investigation of Airway Obstruction Severity Based on Plasma Visfatin Level in Asthmatic Women","authors":"R. Yazdani, M. S. Fekri, S. M. H. Bajgani, Mohsen Shafiepour, Behnam Dalfardi","doi":"10.2174/1573398x19666230315114948","DOIUrl":"https://doi.org/10.2174/1573398x19666230315114948","url":null,"abstract":"\u0000\u0000Bronchial asthma is a chronic disorder with high prevalence among women. Visfatin as a pro-inflammatory adipokine has been linked to inflammatory lung diseases such as asthma and can be used as a forthcoming biomarker target to diagnose and treat asthmatic patients.\u0000\u0000\u0000\u0000Bronchial asthma is a chronic disorder with high prevalence among women. Visfatin as a pro-inflammatory adipokine has been linked to inflammatory lung diseases such as asthma and can be used as a forthcoming biomarker target to diagnose and treat asthmatic patients.\u0000\u0000\u0000\u0000The aim of this study is to evaluate plasma visfatin level and its correlation with pulmonary function of female asthmatic patients.\u0000\u0000\u0000\u0000To evaluate plasma visfatin level and its correlation with pulmonary function of female asthmatic patients.\u0000\u0000\u0000\u0000This cross-sectional study was conducted on all female asthmatic patients referred to the Be'sat Pulmonary Clinic of Kerman from 1 November 2019 to 20 February 2020. Patients with confirmed diagnosis of asthma were included. The data were collected through a checklist and the corresponding author conducted all face-to-face interviews in the physician’s office of the pulmonary clinic. Then, blood samples (5 cc) were taken from the patients to determine the plasma level of visfatin. Data was analyzed by SPSS Software.\u0000\u0000\u0000\u0000113 women with asthma were studied. The mean ± SD age of patients was 46.71 ± 13.91 years (range: 13 to 75). The mean ± SD of visfatin plasma levels was 26.30 ± 6.98 mg/dl (range: 8.50 to 46.88). The forced expiratory volume in the first second (FEV1) had a significant and negative correlation with plasma visfatin concentrations (P-value=0.03).\u0000\u0000\u0000\u0000This cross-sectional study was conducted on all female asthmatic patients referred to the Be''sat Pulmonary Clinic of Kerman from 1 November 2019 to 20 February 2020. Patients with confirmed diagnosis of asthma were included. The data were collected through a checklist and the corresponding author conducted all face-to-face interviews in the physician’s office of the pulmonary clinic. Then, blood samples (5 cc) were taken from the patients to determine the plasma level of visfatin. Data was analyzed by SPSS Software.\u0000\u0000\u0000\u0000The results of this study indicated that plasma visfatin levels were correlated inversely with FEV1 among asthmatic women. Further studies with large samples are recommended to evaluate the role of visfatin in asthma pathogenesis.\u0000\u0000\u0000\u0000113 women with asthma were studied. The mean ± SD age of patients was 46.71 ± 13.91 years (range: 13 to 75). The mean ± SD of visfatin plasma levels was 26.30 ± 6.98 mg/dl (range: 8.50 to 46.88). The forced expiratory volume in the first second (FEV1) had a significant and negative correlation with plasma visfatin concentrations (P-value=0.03).\u0000\u0000\u0000\u0000The results of this study indicated that plasma visfatin levels were correlated inversely with FEV1 among the asthmatic women. Further studies with large samples are recommended to evaluate the role of visfatin in asthma patho","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45834704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-15DOI: 10.2174/1573398x19666230315124509
Mohsen Shafiepour, Sakineh Haj Jafari Nejad, A. Behzadi, Behnam Dalfardi, Ahmad Alinaghi Langari, H. Ahmadipour, A. Shafahi, M. S. Fekri
This study aimed to compare the serum levels of procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the patients with chronic obstructive pulmonary disease (COPD) in the emergency ward of Afzalipour Hospital in Kerman. This study aimed to compare the serum levels of procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the patients with chronic obstructive pulmonary disease (COPD) in the emergency ward of Afzalipour Hospital in Kerman. This cross-sectional study was conducted on 45 patients with stable COPD and 45 patients with AECOPD. Patients were divided into four groups based on COPD severity assessment. Serum procalcitonin levels were measured using an ELISA kit. The mean age of patients in the exacerbation and the stable group was 60.97±12.61 and 62.53±11.04 years, respectively. Serum procalcitonin levels in two exacerbation groups (215.22±19.84) were higher than stable groups (127.92±8.97) (P=0.001). The accuracy of this test for diagnosing acute attack in terms of AECOPD was 77%, and the serum procalcitonin level of 132.6 was found to be the best cut-off point to diagnose acute disease. The mean serum procalcitonin levels of stage D patients in the acute attack group were substantially higher than those of stages D and B patients in the stable group (P = 0.001). Serum procalcitonin levels were related to body mass index (P=0.01), post-bronchodilator FEV1/FVC (P=0.028), and the number of hospitalizations per year (P=0.001). By increasing the serum procalcitonin levels, BMI and number of admissions per year increase, and post-bronchodilator FEV1/FVC decreases. This cross-sectional study was conducted on 45 patients with stable COPD and 45 patients with AECOPD. Patients were divided into four groups based on COPD severity assessment. Serum procalcitonin levels were measured using an ELISA kit. The mean serum levels of procalcitonin in the group with attacks due to COPD was significantly higher than the stable group. The mean age of patients in the exacerbation and the stable group was 60.97±12.61 and 62.53±11.04 years, respectively. Serum procalcitonin levels in two exacerbation groups (215.22±19.84) were higher than stable groups (127.92±8.97) (P=0.001). The accuracy of this test for diagnosing acute attack in terms of AECOPD was 77%, and the serum procalcitonin level of 132.6 was found to be the best cut-off point to diagnose acute disease. The mean serum procalcitonin levels of stage D patients in the acute attack group were substantially higher than those of stages D and B patients in the stable group (P = 0.001).Serum procalcitonin levels were related to body mass index (P=0.01), post-bronchodilator FEV1/FVC (P=0.028), and the number of hospitalizations per year (P=0.001). By increasing the serum procalcitonin levels, BMI and number of admissions per year increase, and post-bronchodilator FEV1/FVC decreases.
{"title":"Comparison of Serum Procalcitonin Levels between Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and Patients with Chronic Obstructive Pulmonary Disease","authors":"Mohsen Shafiepour, Sakineh Haj Jafari Nejad, A. Behzadi, Behnam Dalfardi, Ahmad Alinaghi Langari, H. Ahmadipour, A. Shafahi, M. S. Fekri","doi":"10.2174/1573398x19666230315124509","DOIUrl":"https://doi.org/10.2174/1573398x19666230315124509","url":null,"abstract":"\u0000\u0000This study aimed to compare the serum levels of procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the patients with chronic obstructive pulmonary disease (COPD) in the emergency ward of Afzalipour Hospital in Kerman.\u0000\u0000\u0000\u0000This study aimed to compare the serum levels of procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the patients with chronic obstructive pulmonary disease (COPD) in the emergency ward of Afzalipour Hospital in Kerman.\u0000\u0000\u0000\u0000This cross-sectional study was conducted on 45 patients with stable COPD and 45 patients with AECOPD. Patients were divided into four groups based on COPD severity assessment. Serum procalcitonin levels were measured using an ELISA kit.\u0000\u0000\u0000\u0000The mean age of patients in the exacerbation and the stable group was 60.97±12.61 and 62.53±11.04 years, respectively. Serum procalcitonin levels in two exacerbation groups (215.22±19.84) were higher than stable groups (127.92±8.97) (P=0.001). The accuracy of this test for diagnosing acute attack in terms of AECOPD was 77%, and the serum procalcitonin level of 132.6 was found to be the best cut-off point to diagnose acute disease. The mean serum procalcitonin levels of stage D patients in the acute attack group were substantially higher than those of stages D and B patients in the stable group (P = 0.001). Serum procalcitonin levels were related to body mass index (P=0.01), post-bronchodilator FEV1/FVC (P=0.028), and the number of hospitalizations per year (P=0.001). By increasing the serum procalcitonin levels, BMI and number of admissions per year increase, and post-bronchodilator FEV1/FVC decreases.\u0000\u0000\u0000\u0000This cross-sectional study was conducted on 45 patients with stable COPD and 45 patients with AECOPD. Patients were divided into four groups based on COPD severity assessment. Serum procalcitonin levels were measured using an ELISA kit.\u0000\u0000\u0000\u0000The mean serum levels of procalcitonin in the group with attacks due to COPD was significantly higher than the stable group.\u0000\u0000\u0000\u0000The mean age of patients in the exacerbation and the stable group was 60.97±12.61 and 62.53±11.04 years, respectively. Serum procalcitonin levels in two exacerbation groups (215.22±19.84) were higher than stable groups (127.92±8.97) (P=0.001). The accuracy of this test for diagnosing acute attack in terms of AECOPD was 77%, and the serum procalcitonin level of 132.6 was found to be the best cut-off point to diagnose acute disease. The mean serum procalcitonin levels of stage D patients in the acute attack group were substantially higher than those of stages D and B patients in the stable group (P = 0.001).Serum procalcitonin levels were related to body mass index (P=0.01), post-bronchodilator FEV1/FVC (P=0.028), and the number of hospitalizations per year (P=0.001). By increasing the serum procalcitonin levels, BMI and number of admissions per year increase, and post-bronchodilator FEV1/FVC decreases.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42012369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-14DOI: 10.2174/1573398x19666230314124411
Rozita Khodashahi, Mahnaz Mozdourian, M. Aliakbarian
Considering the importance of assessing solid organ transplants, infected individuals with coronavirus disease 2019 (COVID-19), and the lack of information in this regard, this descriptive study aimed to investigate the clinical features, immunosuppressive agents, and outcomes of liver transplant recipients in the critical phase of infection with COVID-19. This descriptive cross-sectional study was conducted on 12 critically ill liver transplant recipients referred to Imam Reza and Montaseriyeh hospitals affiliated with Mashhad University of Medical Sciences, Mashhad, Iran, within 2020-21. The required data, including demographic and clinical information, were gathered and recorded in a checklist, and the correlations between variables were assessed in SPSS software (version 24). Hypertension, diabetes, and chronic kidney disease were reported in 83.3% (n=10), 58.3% (n=7), and 41.6% (n=5) of patients, respectively. The administration of Mycophenolic acid was correlated with conjunctivitis (r=-0.67; P=0.02), weakness (r=0.77; P=0.006), and sore throat (r=-0.67; P=0.02). Ground glass opacity was reported in all patients, which was along with consolidation in 90.9% of the cases, and acute pulmonary embolism was found in 36.3% of the subjects. Finally, 66.7% (n=8) of patients passed away. Among immunosuppressive agents, only the use of Mycophenolic acid was correlated with the outcome (r=-0.77; P=0.006). This descriptive cross-sectional study was conducted on 12 critically ill liver transplant recipients referred to Imam Reza and Montaseriyeh hospitals affiliated to Mashhad University of Medical silences, Mashhad, Iran, within 2020-21. This study was extracted from a thesis to obtain a specialist MD degree in infectious diseases (Code: 981818). The required data, including demographic and clinical information, were gathered and recorded in a checklist, and the correlations between variables were assessed in SPSS software (version 24). Due to the high rate of mortality among liver transplant recipients in the critical phase of COVID-19, earlier and more aggressive treatment with antiviral and antibacterial agents should be performed in this group of patients. none
{"title":"The Outcome of Critical-phase COVID-19 in Liver Transplant Recipients","authors":"Rozita Khodashahi, Mahnaz Mozdourian, M. Aliakbarian","doi":"10.2174/1573398x19666230314124411","DOIUrl":"https://doi.org/10.2174/1573398x19666230314124411","url":null,"abstract":"\u0000\u0000Considering the importance of assessing solid organ transplants, infected individuals with coronavirus disease 2019 (COVID-19), and the lack of information in this regard, this descriptive study aimed to investigate the clinical features, immunosuppressive agents, and outcomes of liver transplant recipients in the critical phase of infection with COVID-19.\u0000\u0000\u0000\u0000This descriptive cross-sectional study was conducted on 12 critically ill liver transplant recipients referred to Imam Reza and Montaseriyeh hospitals affiliated with Mashhad University of Medical Sciences, Mashhad, Iran, within 2020-21. The required data, including demographic and clinical information, were gathered and recorded in a checklist, and the correlations between variables were assessed in SPSS software (version 24).\u0000\u0000\u0000\u0000Hypertension, diabetes, and chronic kidney disease were reported in 83.3% (n=10), 58.3% (n=7), and 41.6% (n=5) of patients, respectively. The administration of Mycophenolic acid was correlated with conjunctivitis (r=-0.67; P=0.02), weakness (r=0.77; P=0.006), and sore throat (r=-0.67; P=0.02). Ground glass opacity was reported in all patients, which was along with consolidation in 90.9% of the cases, and acute pulmonary embolism was found in 36.3% of the subjects. Finally, 66.7% (n=8) of patients passed away. Among immunosuppressive agents, only the use of Mycophenolic acid was correlated with the outcome (r=-0.77; P=0.006).\u0000\u0000\u0000\u0000This descriptive cross-sectional study was conducted on 12 critically ill liver transplant recipients referred to Imam Reza and Montaseriyeh hospitals affiliated to Mashhad University of Medical silences, Mashhad, Iran, within 2020-21. This study was extracted from a thesis to obtain a specialist MD degree in infectious diseases (Code: 981818). The required data, including demographic and clinical information, were gathered and recorded in a checklist, and the correlations between variables were assessed in SPSS software (version 24).\u0000\u0000\u0000\u0000Due to the high rate of mortality among liver transplant recipients in the critical phase of COVID-19, earlier and more aggressive treatment with antiviral and antibacterial agents should be performed in this group of patients.\u0000\u0000\u0000\u0000none\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42598361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-14DOI: 10.2174/1573398x19666230314161859
M. Contieri, C. Indolfi, S. Vitale, Angela Klain, G. Dinardo, F. Decimo, M. Miraglia Del Giudice
Children with mild or asymptomatic COVID-19 represent the majority of paediatric cases. Hospitalisation and critical care are required only in a small proportion of SARS-CoV-2 positive children who present severe symptoms, like interstitial lung disease. A quarter of children experience persistent symptoms some months later after being hospitalised, and they need to be properly followed up. The authors describe a case report of long-COVID in a 5 years old child, who was previously hospitalized for a severe case of COVID-19 (an interstitial lung disease requiring oxygen), followed up in 3 months in our Pediatric Department. After 3 months post-hospitalisation, despite his clinic history, the clinical examination was normal, during the six-minute walking test he did not desaturate, the spirometry was in the norm and the lung ultrasound did not show any pathological findings. We reported a case of a child previously hospitalised for interstitial lung disease with long-COVID, who has been followed up 3 months after the hospitalisation by our Department of Pediatrics of the University ‘Luigi Vanvitelli’. Based on our experience, even in children who have experienced a severe form of COVID-19 disease and who continue to exhibit symptoms, a proper follow-up can demonstrate a full recovery in a few months.
{"title":"Follow-up COVID-19 and lung ultrasound are fundamental to prove full recovery in children with interstitial lung disease requiring oxygen: a case report","authors":"M. Contieri, C. Indolfi, S. Vitale, Angela Klain, G. Dinardo, F. Decimo, M. Miraglia Del Giudice","doi":"10.2174/1573398x19666230314161859","DOIUrl":"https://doi.org/10.2174/1573398x19666230314161859","url":null,"abstract":"\u0000\u0000Children with mild or asymptomatic COVID-19 represent the majority of paediatric cases. Hospitalisation and critical care are required only in a small proportion of SARS-CoV-2 positive children who present severe symptoms, like interstitial lung disease. A quarter of children experience persistent symptoms some months later after being hospitalised, and they need to be properly followed up.\u0000\u0000\u0000\u0000The authors describe a case report of long-COVID in a 5 years old child, who was previously hospitalized for a severe case of COVID-19 (an interstitial lung disease requiring oxygen), followed up in 3 months in our Pediatric Department.\u0000\u0000\u0000\u0000After 3 months post-hospitalisation, despite his clinic history, the clinical examination was normal, during the six-minute walking test he did not desaturate, the spirometry was in the norm and the lung ultrasound did not show any pathological findings.\u0000\u0000\u0000\u0000We reported a case of a child previously hospitalised for interstitial lung disease with long-COVID, who has been followed up 3 months after the hospitalisation by our Department of Pediatrics of the University ‘Luigi Vanvitelli’. Based on our experience, even in children who have experienced a severe form of COVID-19 disease and who continue to exhibit symptoms, a proper follow-up can demonstrate a full recovery in a few months.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46304197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-14DOI: 10.2174/1573398x19666230214093112
O. Hassanin, K. Al Oweidat, N. Al-Husban, Israa Ayed Al-Odat, Joud Osama Baki, Liyana Hassan Oweis, Hala Yousef, F. Alnaimat, S. A. Alryalat
COVID-19 pandemic affected smokers’ behavior globally. Our objective was to explore changes in smokers’ behavior in Jordan during the pandemic by studying changes in smoking intensity and purchase of smoking products, and by assessing participants’ knowledge and perception of COVID-19. This is a cross-sectional study where convenience sampling was used. An electronic questionnaire was distributed on social media. We included current smokers, aged 18 years or older, living in Jordan at the time of participating in the study. We gathered personal information and smoking history. We assessed the participants’ knowledge about COVID-19 and the change in their smoking behavior and thoughts and attempts to quit smoking. A total of 767 participants were included; the majority, 526(68.6%), were 18-25 years old. 358 (46.7%) have been smokers for one to five years; the predominantly used smoking product was cigarettes (60.1%). Regarding daily smoking behavior during the Covid-19 pandemic, 236(30.8%) participants increased their daily smoking behavior, mainly due to anxiety followed by boredom and staying at home; 241(31.6%) decreased it due to health concerns about self or others. Intentions of quitting smoking were reported by (51.1%), but only (9.6%) genuinely quit. Compliance with the COVID-19 protection guidelines was significantly associated with age and gender variables (P<0.05) as well as change in daily smoking frequency (P<0.001). A total of 767 participants were included; the majority, 526(68.6%), were 18-25 years old. 358 (46.7%) have been smokers for one to five years; the predominantly used smoking product was cigarettes (60.1%). Regarding daily smoking behavior during the Covid-19 pandemic, 236(30.8%) participants increased their daily smoking behavior, mainly due to anxiety followed by boredom and staying at home; 241(31.6%) decreased it due to health concerns about self or others. Intentions of quitting smoking were reported by (51.1%), but only (9.6%) genuinely quit. Compliance with the COVID-19 protection guidelines was significantly associated with age and gender variables (P<0.05) as well as change in daily smoking frequency (P<0.001).
{"title":"The Effect of the Covid-19 Pandemic on Smokers’ Behavior in Jordan","authors":"O. Hassanin, K. Al Oweidat, N. Al-Husban, Israa Ayed Al-Odat, Joud Osama Baki, Liyana Hassan Oweis, Hala Yousef, F. Alnaimat, S. A. Alryalat","doi":"10.2174/1573398x19666230214093112","DOIUrl":"https://doi.org/10.2174/1573398x19666230214093112","url":null,"abstract":"\u0000\u0000COVID-19 pandemic affected smokers’ behavior globally. Our objective was to explore changes in smokers’ behavior in Jordan during the pandemic by studying changes in smoking intensity and purchase of smoking products, and by assessing participants’ knowledge and perception of COVID-19.\u0000\u0000\u0000\u0000This is a cross-sectional study where convenience sampling was used. An electronic questionnaire was distributed on social media. We included current smokers, aged 18 years or older, living in Jordan at the time of participating in the study. We gathered personal information and smoking history. We assessed the participants’ knowledge about COVID-19 and the change in their smoking behavior and thoughts and attempts to quit smoking.\u0000\u0000\u0000\u0000A total of 767 participants were included; the majority, 526(68.6%), were 18-25 years old. 358 (46.7%) have been smokers for one to five years; the predominantly used smoking product was cigarettes (60.1%). Regarding daily smoking behavior during the Covid-19 pandemic, 236(30.8%) participants increased their daily smoking behavior, mainly due to anxiety followed by boredom and staying at home; 241(31.6%) decreased it due to health concerns about self or others. Intentions of quitting smoking were reported by (51.1%), but only (9.6%) genuinely quit. Compliance with the COVID-19 protection guidelines was significantly associated with age and gender variables \u0000(P<0.05) as well as change in daily smoking frequency (P<0.001).\u0000\u0000\u0000\u0000A total of 767 participants were included; the majority, 526(68.6%), were 18-25 years old. 358 (46.7%) have been smokers for one \u0000to five years; the predominantly used smoking product was cigarettes (60.1%). Regarding daily smoking behavior during the Covid-19 \u0000pandemic, 236(30.8%) participants increased their daily smoking behavior, mainly due to anxiety followed by boredom and staying at home; \u0000241(31.6%) decreased it due to health concerns about self or others. Intentions of quitting smoking were reported by (51.1%), but only \u0000(9.6%) genuinely quit. Compliance with the COVID-19 protection guidelines was significantly associated with age and gender variables \u0000(P<0.05) as well as change in daily smoking frequency (P<0.001).\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44102787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-09DOI: 10.2174/1573398x19666230209101155
M. M, M. B, Geetha Bhaktha, Mahesh Pa, Nagabushan S
Asthma is an important cause of morbidity worldwide. The FOXO3a gene plays an important role in human immune regulation and homeostasis. Loss of function may lead to chronic inflammation and asthma. To evaluate the association between Foxo3a gene polymorphism and susceptibility to asthma. We conducted a case-control study in a tertiary care hospital. Participants answered a questionnaire that collected demographic and clinical information. Asthma was confirmed by pre and post bronchodilator spirometry. Genotyping of the FOXO3a polymorphisms was performed using PCR-RFLP. The study population included 41 cases and 33 controls. Among cases, the heterozygous (CT) genotype frequency was greater compared to wild homozygous (CC) and mutant homozygous (TT) variants. In controls, the wild homozygous (CC) genotype frequency was greater compared to heterozygous and mutant homozygous variants. In the general model, the mutant homozygous (TT) group had significantly higher odds of 7.8 (1.78-34.07) of having asthma compared to the wild homozygous (CC) group. The mutant homozygous (TT) group had greater severity of asthma as compared to the wild homozygous (CC) group. The mutant homozygous group (TT) had much lower lung functions, as compared to the wild homozygous (CC) group in asthmatics. Among non-asthmatic controls, lower lung functions were seen in the mutant (TT) group as compared to the wild (CC) group We found a significant association between the Foxo3a gene polymorphism and asthma. The T allele, a variant of the Foxo3a gene polymorphism, is associated with a higher risk of asthma, and greater asthma severity. It is also associated with lower lung functions in both asthmatics and apparently healthy control subjects. RUNNING TITLE: Foxo3a gene polymorphism and asthma
{"title":"Association between Foxo3a gene polymorphism and susceptibility to asthma in south Indian population","authors":"M. M, M. B, Geetha Bhaktha, Mahesh Pa, Nagabushan S","doi":"10.2174/1573398x19666230209101155","DOIUrl":"https://doi.org/10.2174/1573398x19666230209101155","url":null,"abstract":"\u0000\u0000Asthma is an important cause of morbidity worldwide. The FOXO3a gene plays an important role in human immune regulation and homeostasis. Loss of function may lead to chronic inflammation and asthma.\u0000\u0000\u0000\u0000To evaluate the association between Foxo3a gene polymorphism and susceptibility to asthma.\u0000\u0000\u0000\u0000We conducted a case-control study in a tertiary care hospital. Participants answered a questionnaire that collected demographic and clinical information. Asthma was confirmed by pre and post bronchodilator spirometry. Genotyping of the FOXO3a polymorphisms was performed using PCR-RFLP.\u0000\u0000\u0000\u0000The study population included 41 cases and 33 controls. Among cases, the heterozygous (CT) genotype frequency was greater compared to wild homozygous (CC) and mutant homozygous (TT) variants. In controls, the wild homozygous (CC) genotype frequency was greater compared to heterozygous and mutant homozygous variants. In the general model, the mutant homozygous (TT) group had significantly higher odds of 7.8 (1.78-34.07) of having asthma compared to the wild homozygous (CC) group. The mutant homozygous (TT) group had greater severity of asthma as compared to the wild homozygous (CC) group. The mutant homozygous group (TT) had much lower lung functions, as compared to the wild homozygous (CC) group in asthmatics. Among non-asthmatic controls, lower lung functions were seen in the mutant (TT) group as compared to the wild (CC) group\u0000\u0000\u0000\u0000We found a significant association between the Foxo3a gene polymorphism and asthma. The T allele, a variant of the Foxo3a gene polymorphism, is associated with a higher risk of asthma, and greater asthma severity. It is also associated with lower lung functions in both asthmatics and apparently healthy control subjects.\u0000\u0000\u0000\u0000RUNNING TITLE: Foxo3a gene polymorphism and asthma\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41767647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01DOI: 10.2174/1573398x1901230111152539
N. Hussaini, Sevda Salmasy, J. Varon
{"title":"2023: The Journal, COVID-19, and Traveling in the Future","authors":"N. Hussaini, Sevda Salmasy, J. Varon","doi":"10.2174/1573398x1901230111152539","DOIUrl":"https://doi.org/10.2174/1573398x1901230111152539","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47684531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-17DOI: 10.2174/1573398x19666230117123608
R. Gútierrez-Arias, Carlos Torres-Herrera, Mario Silva-Tetlak, Leonardo Zarate-Vidal, Darwig Burrows-Rojo, María Isabel Vega-Zambrano
Background: Heart rate variability (HRV) analysis is a relevant indicator of autonomic nervous system function over the cardiovascular system. The usual way to measure this variability is from the electrocardiogram (ECG). To assess the validity of HRV measurements obtained from a heart rate monitor (HRM) Polar® V800 in critically ill adult subjects. A prospective, repeated measures, observational study was conducted in two in the Chilean intensive care units. Twenty-one different HRV variables were simultaneously assessed using a Polar® V800 HRMs and an ECG Mortara® H3 Holter device. The data was collected from the clinical record and physical examinations. The evaluations were conducted for 10 minutes at a time and simultaneously, during which the subjects had to remain supine and at rest. The sampling frequency was 1000 Hz, providing a temporal resolution of 1 millisecond for each RR period. Thirty adult subjects were included with an average age of 33.63 ± 8.91 years. When comparing both HRV assessment methods, only 3 variables showed statistically significant differences (p ≤ 0.05). As well, the correlations showed 4 strong and 17 near-perfect associations, which were positive and statistically significant (p ≤ 0.001). In addition, intraclass correlation coefficients (between 0.744 and 1) and bias determined using the Bland-Altman method found both methods to be concordant. The Polar® V800 monitor is a valid tool for assessing HRV in critically ill adult subjects.
{"title":"Validity of heart rate variability measurement by Polar® v800 heart rate monitor in critically ill patients","authors":"R. Gútierrez-Arias, Carlos Torres-Herrera, Mario Silva-Tetlak, Leonardo Zarate-Vidal, Darwig Burrows-Rojo, María Isabel Vega-Zambrano","doi":"10.2174/1573398x19666230117123608","DOIUrl":"https://doi.org/10.2174/1573398x19666230117123608","url":null,"abstract":"\u0000\u0000Background: Heart rate variability (HRV) analysis is a relevant indicator of autonomic nervous system function over the cardiovascular system. The usual way to measure this variability is from the electrocardiogram (ECG).\u0000\u0000\u0000\u0000To assess the validity of HRV measurements obtained from a heart rate monitor (HRM) Polar® V800 in critically ill adult subjects.\u0000\u0000\u0000\u0000A prospective, repeated measures, observational study was conducted in two in the Chilean intensive care units. Twenty-one different HRV variables were simultaneously assessed using a Polar® V800 HRMs and an ECG Mortara® H3 Holter device. The data was collected from the clinical record and physical examinations. The evaluations were conducted for 10 minutes at a time and simultaneously, during which the subjects had to remain supine and at rest. The sampling frequency was 1000 Hz, providing a temporal resolution of 1 millisecond for each RR period.\u0000\u0000\u0000\u0000Thirty adult subjects were included with an average age of 33.63 ± 8.91 years. When comparing both HRV assessment methods, only 3 variables showed statistically significant differences (p ≤ 0.05). As well, the correlations showed 4 strong and 17 near-perfect associations, which were positive and statistically significant (p ≤ 0.001). In addition, intraclass correlation coefficients (between 0.744 and 1) and bias determined using the Bland-Altman method found both methods to be concordant.\u0000\u0000\u0000\u0000The Polar® V800 monitor is a valid tool for assessing HRV in critically ill adult subjects.\u0000","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47152896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：